Interestingly, three different CDKIs 4/6 have recently been FDA approved for the treatment of lifelong aggressive and refractory HR+, Her2- BC therapy (palbociclib, PD0332991; ribociclib, LEE011; abemaciclib, LY835219) [149,150,151]. The gene discussed is ERBB2; the disease is breast cancer.